Scandion Oncology is a biotechnology company focused on developing therapeutics to counter drug resistance in cancer.
More Scandion Oncology content >Investment summary
Scandion Oncology is a biotechnology company focused on the development of therapies to alleviate drug resistance in prevalent cancers. Its most advanced clinical asset, SCO-101, acts via a dual mechanism to sensitise resistant cells to treatment. Scandion aims to target resistant metastatic colorectal cancer (mCRC) and pancreatic cancer with SCO-101. Part 1 of the Phase II trial, CORIST, in mCRC identified a tolerated dose and a good safety profile in July 2021. The proof-of-concept part 2 study is underway. Results from the CORIST and Phase Ib trial, PANTAX, in pancreatic cancer are both expected in Q2–Q322.
Content on Scandion Oncology
Scandion Oncology – Drug-resistant cancer solutions
Healthcare
|
research QuickView
|
14 January 2022



Sector |
---|
Healthcare
Access more Healthcare content
|
Share price graph
Price performance
% |
1m |
3m |
12m |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
*% relative to local index |
You may also be interested in…
- Abliva
- AlzeCure Pharma
- ASIT biotech
- Basilea Pharmaceutica
- BerGenBio
- Cantargia
- Carmat
- Deinove
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- IRLAB Therapeutics
- Kiadis Pharma
- MagForce
- Medigene
- MOLOGEN
- Newron Pharmaceuticals
- Nicox
- Nuevolution
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Pharnext
- Photocure
- Pixium Vision
- Polyphor
- Probiodrug
- RhoVac
- Ryvu Therapeutics
- Sequana Medical
- Targovax
- Transgene
- TxCell
- Ultimovacs
- Vivesto
- Xbrane Biopharma